| Document Date: 2015-01-08 11:26:18
Open Document File Size: 354,96 KBShare Result on Facebook
Company UCB Pharma S.A. / Medicinal Product Pharmaceutical / Wockhardt UK Ltd / / Country France / United Kingdom / Cyprus / Ireland / / Facility II.2 Drug Substance INN / / IndustryTerm pharmaceutical development / pharmaceutical and biological aspects / healthcare professionals / originator product / faced rubber closures / aqueous intravenous solution / chemical messengers / inspection services / reference product / validation protocol / generic product / patients/healthcare professionals / Chemical and physical in-use stability / manufacturing sites / reference products / intravenous product / manufacturing process / / MedicalCondition loss of consciousness / partial-onset seizures / seizures / numbness / primary generalised tonic-clonic seizures / newly diagnosed epilepsy / epilepsy / juvenile myoclonic epilepsy / myoclonic seizures / partial onset seizures / idiopathic generalised epilepsy / / MedicalTreatment adjunctive therapy / / Organization European Directorate for the Quality of Medicines and Healthcare / MHRA / European Union / / Position pharmacist / nurse / / Product Keppra / sodium chloride / acetic acid / dextrose / sodium acetate / / ProgrammingLanguage EC / DC / / Technology Pharmacokinetics / validation protocol / Pharmacodynamics / /
SocialTag |
Levetiracetam Wockhardt 100mg/ml concentrate for solution for infusion UK/H[removed]DC Public Assessment Report